California-based Ansa Biotechnologies secured $54.4 million in Series B funding led by Cerberus Ventures to expand U.S.-based enzymatic DNA synthesis capacity. The company’s innovative DNA manufacturing platform provides reliable production of large DNA constructs up to 50 kb. The financing will enhance customer experience and bolster strategic partnerships. Ansa aims to address longstanding bottlenecks in DNA synthesis by offering rapid, high-fidelity custom DNA solutions to drive advances in synthetic biology and biotechnology research.